We are live on ! Find out more
NWBO

Northwest Biotherapeutics
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

13 hedge funds and large institutions have $630K invested in Northwest Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,083% more capital inflows, than outflows

Capital inflows: $93.3K | Capital outflows: $7.89K

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

7% less funds holding

Funds holding: 14 → 13 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NWBO Hedge Fund Activity: Q2 2022 in Review

13 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q2 2022, worth a combined $630K — up 5% from $600K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of NWBO and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.

The largest buyer was Ancora Advisors, adding an estimated $76.1K. The largest seller was Kovack Advisors, exiting entirely with an estimated $6K sold.

  • 13 institutional investors held Northwest Biotherapeutics (NWBO) as of Q2 2022, down from 14 in Q1 2022.
  • Funds reported $630K of Northwest Biotherapeutics stock for Q2 2022, up 5% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics positions in Q2 2022 and 1 closed out, a net change of -1 holder.
  • The largest Northwest Biotherapeutics buyer in Q2 2022 was Ancora Advisors, an estimated $76.1K added.
  • The largest Northwest Biotherapeutics seller in Q2 2022 was Kovack Advisors, an estimated $6K sold.

Based on aggregated 13F filings for Q2 2022.